Nippon India Pharma Fund Direct Growth

Nippon India Pharma Fund Direct Growth

Equity

Direct

Sector - Healthcare

NAV as on 06-11-2024

₹ 572.46

1%

1D

Inception Returns

19.4%

/yr

About Nippon India Pharma Fund Direct Growth

Nippon India Pharma Fund Direct Growth is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Sailesh Raj Bhan, Kinjal Desai. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. Nippon India Pharma Fund Direct Growth has ₹8769 Cr worth of assets under management (AUM) as on Sep 2024 and is more than category average.
  2. The fund has an expense ratio 0.9.

Returns

Nippon India Pharma Fund Direct Growth has given a CAGR return of 19.44% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 49.16%, 20.89% and 29.47% respectively.

Holdings

Nippon India Pharma Fund Direct Growth has allocated its funds majorly in Health, Cash Equivalent. Its top holdings are Sun Pharmaceuticals Industries Ltd, Divi's Laboratories Ltd, Lupin Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 15%
For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefit
Dividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.

Investment objective of Nippon India Pharma Fund Direct Growth

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. Nippon India Pharma Fund Direct Growth has no lock in period.

Historical NAV & Returns

Annualised

zero opening, trading, fund transfer fee
7290 people have invested ₹ 2.9Cr in Nippon India Pharma Fund Direct Growth in the last three months

INDmoney Rank for Nippon India Pharma Fund Direct Growth

Powered by IND quant engine
IND ranking is not available for this fund.
img
Among most bought funds within the category
img
Larger AUM within category
img
Beats FD returns for both 3Y & 5Y duration
img
5Y returns in the bottom 25% of the category
img
3Y returns in the bottom 25% of the category

Nippon India Pharma Fund Direct Growth Overview

Expense ratio0.91%
Benchmark
S&P BSE Healthcare PR
AUM₹8769 Cr
Inception Date1 January, 2013
Min Lumpsum/SIP₹5000/₹100
Exit Load
1.0%
Lock InNo Lock-in
TurnOver
16.09%
STCGRedeeming before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

Trailing Returns

as on (06-Nov-24)

Period
Nippon India Pharma Fund Direct Growth
Nifty 500
sector - healthcare
1M
0.1%
-2.1%
1.1%
3M
6.4%
2.6%
9.1%
6M
20.1%
10.4%
23.6%
1Y
49.2%
34.2%
56.4%
3Y
20.9%
14.4%
20.3%
5Y
29.5%
18.8%
28.4%

Fund Distribution

as on (30-Sep-24)

  • Equity 96.3%

  • Debt & Cash 3.7%

Large cap
46.3%

Mid cap
27.6%

Small cap
20.6%

Sector Allocation

Sep'24

Aug'24

Jul'24

Health
100%
All changes are between Jul'24 and Sep'24
Sep'24
Aug'24
Jul'24
Fund Returns
0.87%
6.09%
9.79%
Nifty 500
2.04%
0.97%
3.53%
  • This fund’s returns stands at 0.87% whereas the fund’s underlying benchmark Nifty 500 returns stands at 2.04% as on Sep'24
  • This fund underperformed Nifty 500 by 1.17% in Sep'24
Parameters
Sep'24
Aug'24
Jul'24
AUM
₹ 8.8K Cr
₹ 8.6K Cr
₹ 8.1K Cr
  • AUM of the fund stands at 8.8K Cr as of Sep'24
  • AUM increased by 120.7 Cr between Sep'24 and Aug'24
Top Stocks bought last month
Sun Pharmaceuticals Industries Ltd's allocation increased from 13.81% to 14.41%
Sun Pharmaceuticals Industries Ltd's allocation increased from 13.81% to 14.41%
Divi's Laboratories Ltd's allocation increased from 7.96% to 8.39%
Divi's Laboratories Ltd's allocation increased from 7.96% to 8.39%
Apollo Hospitals Enterprise Ltd's allocation increased from 5.2% to 5.33%
Apollo Hospitals Enterprise Ltd's allocation increased from 5.2% to 5.33%
Top Stocks sold last month
Lupin Ltd's allocation decreased from 8.3 % to 8.01 %
Lupin Ltd's allocation decreased from 8.3 % to 8.01 %
Cipla Ltd's allocation decreased from 5.93 % to 5.85 %
Cipla Ltd's allocation decreased from 5.93 % to 5.85 %
Dr Reddy's Laboratories Ltd's allocation decreased from 5.69 % to 5.39 %
Dr Reddy's Laboratories Ltd's allocation decreased from 5.69 % to 5.39 %
Mid Cap allocation has gone down from 33.9% to 27.6%
Mid Cap allocation has gone down from 33.9% to 27.6%
Large Cap allocation has gone up from 43.2% to 46.3%
Large Cap allocation has gone up from 43.2% to 46.3%
Small Cap allocation has gone up from 18.9% to 20.6%
Small Cap allocation has gone up from 18.9% to 20.6%
Cash allocation has gone up from 2.6% to 3.7%
Cash allocation has gone up from 2.6% to 3.7%

Top Sector in September was Health

Sep'24
Health
100%
Aug'24
Health
100%
  • Equity

Fund
Sep'24
Aug'24
Jul'24
No of Holdings
36
36
35
Top 5 Company Concentration
42%
41.7%
41.2%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (14.4%)
Sun Pharmaceuticals Industries Ltd (13.8%)
Sun Pharmaceuticals Industries Ltd (13.8%)
No of Sectors
1
1
1
Top 5 Sectors Concentration
100%
100%
100%
Sector having highest exposure
Health (100%)
Health (100%)
Health (100%)
Loading...
We are taking more time than usual
Sailesh Raj Bhan
Sailesh Raj Bhan
Fund Manager of Nippon India Pharma Fund Direct Growth, since 1 April 2005
Kinjal Desai
Kinjal Desai
Fund Manager of Nippon India Pharma Fund Direct Growth, since 25 May 2018
Fund House
Nippon Life India Asset Management Ltd
Total Schemes
Total AUM
₹4.07L Cr
as on 30-Sep-2024
Address
Nippon Life India Asset Management Limited,4th Floor, Tower A, Peninsula Business Park,,Ganapatrao Kadam Marg,,Lower Parel (W)
Phone
022-68087000/18602660111
Website
customercare@nipponindiaim.in

Mutual Fund Insights

Insights icon
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.91% which is lower than the category average expense ratio of 1.39%.
Insights icon
This fund with AUM at ₹8768.66Cr is among the largest funds in the sector - healthcare category.
Insights icon
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 66.63% return, outperforming this fund by 17.47%.
Insights icon
In the last 3 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 25.4% return, outperforming this fund by 4.51% per annum.
Insights icon
Over the last 1 year, this fund has decreased expense ratio by 9.9% moving from 1.01 to 0.91.
Insights icon
In the last 5 years, DSP Healthcare Fund Direct Growth has given 33.29% return, outperforming this fund by 3.82% per annum.

Nippon India Pharma Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 19.44% since inception which is less than its category average return of 27.47%
Fund Allocations

Fund Allocations

This fund has an allocation of 96.26% in Equity, 0% in Debt and 3.74% in Cash related instruments
AUM size ₹8769 Cr

AUM size ₹8769 Cr

This fund has AUM of ₹8769 Cr which is more than its category average of ₹ 2127 Cr
Expense Ratio 0.91%

Expense Ratio 0.91%

This fund has an expense ratio of 0.91% which is less than its category average expense ratio of 1.42%

Frequently Asked Questions for Nippon India Pharma Fund Direct Growth

The current NAV of Nippon India Pharma Fund Direct Growth is ₹572.46 as on 06-Nov-2024.
Existing (Absolute + CAGR) as on 06-Nov-2024.
Nippon India Pharma Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
0.13%
0.13%
6 Month Returns
20.15%
20.15%
1 Year Returns
49.16%
49.16%
3 Years Returns
76.66%
20.89%
5 Years Returns
263.81%
29.47%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.91% as on October 2024
₹8769 Cr as on October 2024
Sun Pharmaceuticals Industries Ltd(14.41%), Divi's Laboratories Ltd(8.39%), Lupin Ltd(8.01%), Cipla Ltd(5.85%), Dr Reddy's Laboratories Ltd(5.39%) as on October 2024
The alpha ratio for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
Nippon India Pharma Fund Direct Growth
-2.6
0.59
2.62
As on October 2024
The alpha for Nippon India Pharma Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
Nippon India Pharma Fund Direct Growth
0.91
0.92
0.92
As on October 2024
The Beta for Nippon India Pharma Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
Nippon India Pharma Fund Direct Growth
2.69
0.95
1.22
As on October 2024
The sharpe ratio for Nippon India Pharma Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
Nippon India Pharma Fund Direct Growth
13.73
15.09
18.45
As on October 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.73 as on October 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Sailesh Raj Bhan, Kinjal Desai are the fund managers of Nippon India Pharma Fund Direct Growth
The Exit load of Nippon India Pharma Fund Direct Growth is 1%